Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study.

ABSTRACT:

Background

New screening techniques may affect the optimal approaches for the prevention of cervical cancer. We evaluated the cost-effectiveness and accuracy of alternative screening strategies to provide evidence for cervical cancer screening guidelines in China.

Methods

In total, 32,306 women were enrolled. The current screening with Cervista^® high-risk human papillomavirus (HR-HPV) nongenotyping and cytology cotesting (Cervista^® cotesting) was compared with PCR-reverse dot blot HR-HPV genotyping and cytology cotesting (PCR-RDB cotesting). All eligible participants were divided into Arm 1, in which both HR-HPV assays were performed, and Arms 2 and 3, in which the PCR-RDB HPV or Cervista^® HR-HPV assay, respectively, was performed. Outcome in

SUBMITTER: Dong B 

PROVIDER: S-EPMC7453699 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature